Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Compass Diversified Q4 2025 Earnings Call - Deleveraging Takes Center Stage as Management Launches Multiple Sale Processes
Compass Diversified spent 2025 absorbing the Lugano shock and restatement pain, but the business that remains is generating healthy underlying cash flow. Excluding Lugano, CODI posted $1.8 billion in ...
- Excluding Lugano, CODI reported FY2025 net sales of $1.8 billion, up 3.9%, and Subsidiary Adjusted EBITDA of $345.8 million, up 8.8%. Consumer Adjusted EBITDA grew 13.8%, industrial up 1.1%.
- GAAP results were hit hard by Lugano. Q4 GAAP net loss was $78.8 million, including more than $25 million in one-time Lugano investigation and restatement costs; full-year GAAP net loss was $293.7 million, including roughly $60 million of investigation and restatement-related expenses.
- Lugano was deconsolidated as of November 16, 2025 and is in Chapter 11, creating an ongoing overhang and complicating disclosures and capital-markets timing.
- +12 more takeaways
Innodata Q4 2025 Earnings Call - Data-first bet sets 35% growth guide across generative, agentic and physical AI
Innodata closed FY2025 with strong top-line momentum, reporting Q4 revenue of $72.4 million, up 22% year-over-year, and full-year revenue of $251.7 million, up 48% versus prior year. Adjusted gross ma...
- Q4 2025 revenue $72.4 million, up 22% year-over-year; FY2025 revenue $251.7 million, up 48% year-over-year.
- Q4 adjusted gross margin 42%, above the externally communicated 40% target.
- Q4 adjusted EBITDA $15.7 million, 22% of revenue, beating analyst consensus by $1.2 million; net income for the quarter was $8.8 million.
- +12 more takeaways
Sunrun Q4 2025 Earnings Call - Margin-First Pivot: storage-led growth, new JV financing, and cash generation focus
Sunrun closed 2025 with a clear, deliberate pivot away from top-line volume at all costs toward higher-margin, storage-first growth and capital innovation. Management reported flat subscriber addition...
- Sunrun ended 2025 with 108,000 subscriber additions, roughly flat year-over-year, and about 25,000 additions in Q4.
- Full-year Cash Generation was $377 million in 2025; Q4 Cash Generation was $187 million.
- Sunrun increased its storage attachment rate to 71% exiting 2025, a 9 percentage point improvement year-over-year, and grew storage capacity installed by 26% in 2025.
- +13 more takeaways
Definium Therapeutics Full Year 2025 Earnings Call - DT120 Phase 3 Readouts Imminent; Emerge (MDD) Late Q2, Voyage (GAD) Early Q3, Cash into 2028
Definium heads into a make-or-break 2026 with DT120 ODT front and center. Emerge, the first pivotal MDD trial, is fully enrolled with topline due late Q2, Voyage (GAD) is roughly 80% enrolled with top...
- DT120 ODT is the companys lead program with three Phase 3 readouts expected in 2026; Emerge (MDD) is fully enrolled and topline is expected late Q2 2026.
- Voyage (GAD) is approximately 80% enrolled, completed a blinded sample size re-estimation with no increase required, and topline is expected early Q3 2026.
- Panorama (second GAD pivotal) is enrolling rapidly, includes European sites, and management will disclose its blinded sample size re-estimation and further enrollment details at Analyst Day in April.
- +12 more takeaways
TeraWulf Q4 & FY2025 Earnings Call - Pivoting from Mining to Power‑Backed AI Infrastructure with Google‑Backed 450 MW Lease
TeraWulf spent 2025 deliberately remaking itself. The company bought Beowulf Electricity & Data, closed long-duration site control deals (Cayuga, Kentucky, Morgantown/Chesapeake) and signed credit-enh...
- 2025 was a structural year: TeraWulf acquired Beowulf Electricity & Data to internalize power generation expertise and remove related‑party complexity.
- Signature commercial validation: a 450 MW lease with Fluidstack is credit‑enhanced by Google, and Google warrants will make it the company’s largest shareholder.
- Site control and brownfield strategy emphasized: Cayuga offers up to 400 MW at a retired coal facility; Morgantown (Chesapeake) is being engineered as a net generator, targeting ~500 MW of new dispatchable generation, 250 MW battery storage and 500 MW of data center load in phase one.
- +12 more takeaways
Talen Energy Corporation Q4 2025 Earnings Call - Reaffirmed 2026 Guidance While Pressing the 'Flywheel' on Data Center Power and Closing Cornerstone
Talen closed 2025 with stronger-than-expected results and opened 2026 by reaffirming guidance, leaning into a strategy to convert merchant generation into contracted infrastructure for data centers. M...
- Company reaffirmed 2026 guidance: adjusted EBITDA $1.75 billion to $2.05 billion, adjusted free cash flow $980 million to $1.18 billion.
- 2025 reported adjusted EBITDA of $1.035 billion and adjusted free cash flow of $524 million, both above prior guidance ranges.
- Q4 2025 results: adjusted EBITDA $382 million and adjusted free cash flow $292 million, with Q4 AFFCF exceeding full-year 2024.
- +12 more takeaways
Solventum Q4 2025 Earnings Call - Gaining Momentum Despite Separation Headwinds, Accelerating Toward Long-Range Targets
Solventum closed its first full year as a standalone company with visible commercial momentum, reporting $2.0 billion in Q4 sales, 3.5% organic growth for the quarter and 3.3% organic growth for the f...
- Q4 sales were $2.0 billion, up 3.5% organic in the quarter and down 3.7% reported due to the P&F divestiture and Acera acquisition effects.
- Full-year 2025 organic sales growth was 3.3%, normalized to roughly 3.5% after adjusting for SKU exits and dental backorder improvement.
- MedSurg and Dental outperformed in Q4; MedSurg organic +3.2% and Dental organic +5.9% (but Dental normalized closer to 3% after backorder benefit).
- +13 more takeaways
Syndax Pharmaceuticals Q4 2025 Earnings Call - Two launches fuel $172M year, Revuforj NPM1 ramp and axatilimab IPF readout set the bar for 2026
Syndax closed 2025 as a commercial biotech in earnest, delivering $172.4 million in revenue driven by two launches. Revuforj generated $124.8 million in its first full year and accelerated in Q4 as th...
- Syndax reported $172.4 million total revenue in 2025, comprised of $124.8 million Revuforj net revenue, $42.4 million Niktimvo collaboration revenue, and $5.1 million milestones/royalties.
- Revuforj accelerated in Q4 with $44.2 million in net revenue, up 38% sequentially, and total prescriptions increased about 35% quarter over quarter.
- Approximately 1,050 patients have been treated commercially with Revuforj since launch, and Syndax estimates near 50% penetration of the KMT2A incident population within the first year.
- +12 more takeaways
Crinetics Pharmaceuticals Q4 2025 Earnings Call - PALSONIFY launch gains traction as company pivots to a commercial-stage endocrinology franchise
Crinetics closed 2025 as a commercial-stage company, with PALSONIFY driving an early U.S. launch while the pipeline advances. Q4 product revenue was $5.4 million, enrollment activity accelerated with ...
- PALSONIFY commercial launch underway: Q4 net product revenue of $5.4 million, contributing to Q4 total net revenue of $6.2 million and FY 2025 revenue of $7.7 million.
- Launch traction metrics: more than 200 enrollment forms in Q4 and prescriptions from over 125 unique prescribers across community and pituitary centers.
- Payer access early momentum: management reports formulary wins with several major plans, straightforward prior authorizations aligned to label language and no onerous step edits so far; medical exceptions being used for broader coverage.
- +11 more takeaways
PubMatic Q4 2025 Earnings Call - Agentic AI Leadership Sparks Inflection, Sets Stage for Double-Digit H2 2026 Growth
PubMatic says Q4 marked a structural inflection: revenue and adjusted EBITDA beat expectations, driven by CTV, mobile app, and rapidly scaling AI products. Management highlighted AgenticOS and Activat...
- Q4 and full-year 2025 marked an inflection: PubMatic beat guidance on revenue and adjusted EBITDA, reporting Q4 adjusted EBITDA of $27.8M, a 35% margin.
- Management repeatedly flagged agentic AI as the defining secular tailwind; AgenticOS and Agentic campaigns are core strategic differentiators being scaled.
- Agentic adoption: PubMatic has run over 250 agentic deals, launched an Agentic AI Accelerator with ~100 applicants, and reports early proof points including a 5x campaign cost efficiency.
- +13 more takeaways